Nuvectis Pharma
NVCT
33 hedge funds and large institutions have $16.5M invested in Nuvectis Pharma in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 5 closing their positions.
12% more capital inflows, than outflows
Capital inflows: $2.19M | Capital outflows: $1.96M
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0.41% less ownership
Funds ownership: 7.83% → 7.41% (-0.41%)
11% less funds holding
Funds holding: 37 → 33 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$651K |
| 2 |
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$381K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$365K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$248K |
| 5 |
Moran Wealth Management
Naples,
Florida
|
+$242K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
J.M. Forbes & Co
Boston,
Massachusetts
|
-$478K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$448K |
| 3 |
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$364K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$200K |
| 5 |
Renaissance Technologies
New York
|
-$159K |
NVCT Hedge Fund Activity: Q3 2023 in Review
33 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q3 2023, worth a combined $16.5M — down 18% from $20M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NVCT and 1 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was BlackRock, adding an estimated $651K. The largest seller was J.M. Forbes & Co, cutting an estimated $478K.
- 33 institutional investors held Nuvectis Pharma (NVCT) as of Q3 2023, down from 37 in Q2 2023.
- Funds reported $16.5M of Nuvectis Pharma stock for Q3 2023, down 18% quarter-over-quarter.
- 1 fund opened new Nuvectis Pharma positions in Q3 2023 and 5 closed out, a net change of -4 holders.
- The largest Nuvectis Pharma buyer in Q3 2023 was BlackRock, an estimated $651K added.
- The largest Nuvectis Pharma seller in Q3 2023 was J.M. Forbes & Co, an estimated $478K sold.
Based on aggregated 13F filings for Q3 2023.